Beacon Pharma, a leading company in the country’s pharmaceutical sector, has nearly doubled its profit in the fiscal year 2024-25. The company’s profit reached BDT 950 million, compared to BDT 520 million in the previous fiscal year 2023-24. This represents an increase of BDT 430 million or approximately 83 percent within one year.
On Wednesday (October 22), the company’s board of directors finalized the financial statements for the fiscal year 2024-25 and confirmed this profit figure. As a listed company on the stock market, this information was disclosed to investors today, Thursday, through the Dhaka Stock Exchange (DSE).
At the same meeting, the company decided to distribute a 21 percent cash dividend to investors. However, the founders and directors will not receive any dividend.
Beacon Pharma, which manufactures and markets medicines for cancer and various other diseases, will distribute a total dividend of BDT 290 million, of which BDT 185.4 million will go to institutional investors. Approximately 38 percent of the company’s shares are held by institutional investors. Individual retail investors hold about 22 percent of the shares and will receive BDT 106.4 million as dividends.
The company has set November 16 as the record date for dividend distribution. Shareholders holding shares on that date will be eligible to receive the dividend. In the fiscal year 2023-24, the company paid dividends at the rate of 20 percent to general and institutional investors and 10 percent to founders and directors.
Beacon Pharma has not yet disclosed full business details for the fiscal year 2024-25. However, according to the financial report for nine months from July to March, the company conducted business worth BDT 8.99 billion and earned a profit of BDT 865 million. Approximately BDT 100 million profit was made in the remaining three months.
Following the announcement of profit and dividends, the company’s share price rose by 1.5 percent or BDT 1.5 today to reach BDT 109. Nearly 100,000 shares were traded on the Dhaka Stock Exchange, with a market value exceeding BDT 10 million.
Beacon Pharma started its operations in 2006 and was listed on the stock market in 2010. With a capital of BDT 2.31 billion, the company is recognized as a fundamentally strong ‘A’ category company.